** Shares of Prescient Therapeutics PTX.AX rise as much as 28.6% to A$0.054, hit their highest levels since February 11
** The clinical-stage oncology co says it received the US FDA Fast-Track designation for PTX-100, a treatment for adults with relapsed or refractory mycosis fungoides
** PTX-100 is a compound with the ability to block an important cancer growth enzyme, says co
** The fast-track status is an important step towards commercialisation of the drug, says co
** About 2.7 million shares change hands, 4.3 times the 30-day average volume of shares
** Stock down 16% this year, as of last close
(Reporting by Sherin Sunny in Bengaluru)
((Sherin.Sunny@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。